Holen Sie sich die Stockscreener-App
3.47
0.85%
-0.07
Handel nachbörslich:
3.47
Schlusskurs vom Vortag:
$3.54
Offen:
$3.61
24-Stunden-Volumen:
7,615
Relative Volume:
0.91
Marktkapitalisierung:
$176.67M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-4.7269
EPS:
-0.7341
Netto-Cashflow:
-
1W Leistung:
-8.36%
1M Leistung:
-8.59%
6M Leistung:
-16.71%
1J Leistung:
-6.24%
1-Tages-Spanne:
$3.45
$3.63
1-Wochen-Bereich:
$3.45
$3.90
52-Wochen-Spanne:
$3.35
$6.4229
Genfit Adr Stock (GNFT) Company Profile
Vergleichen Sie GNFT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNFT
Genfit Adr
|
3.47 | 176.67M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
479.79 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
698.74 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.67 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.75 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
271.80 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Genfit Adr Stock (GNFT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-12-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-07-23 | Hochstufung | Stifel | Hold → Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Underperform |
| 2020-05-13 | Herabstufung | Kepler | Buy → Reduce |
| 2020-05-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-05-12 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2019-10-29 | Bestätigt | B. Riley FBR | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-04-24 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-22 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Genfit Adr Aktie (GNFT) Neueste Nachrichten
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
GENFIT annonce les résultats préliminaires de l’Offre de Rachat proposée aux porteurs d’OCEANEs 2025 et la Convocation de l’assemblée générale des porteurs d’OCEANEs 2025 - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Up 1% for Week - TradingView
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Move Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Decrease Friday - MSN
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading - MSN
GENFIT: Historic Milestone Achieved with U.S. FDA - GlobeNewswire
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen
Ipsen und GENFIT schließen im Rahmen einer langfristigen globalen Partnerschaft eine exklusive Lizenzvereinbarung für Elafibranor ab, ein Phase-III-Asset, das für die Behandlung von primärer biliärer Cholangitis geprüft wird - Business Wire
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire
The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO - Yahoo Finance
Finanzdaten der Genfit Adr-Aktie (GNFT)
Es liegen keine Finanzdaten für Genfit Adr (GNFT) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
2.95%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):